Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX): DMC Approves Phase III Study Of Firdapse

Boston, MA 10/22/2013 (wallstreetpr) – After the Data Monitoring Committee (DMC) approval, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) will now continue with the pivotal phase III clinical trial of Firdapse in the U.S. and Europe. This drug is geared towards the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). This follows DMC’s clinical data and safety reviews on the drug. […]